Where Is The Patient Voice In Alzheimer's Disease Drug Development?
This article was originally published in The Pink Sheet Daily
Companies focused on Alzheimer's R&D need to catch up on patient involvement, and earlier diagnosis may help, patient advocate suggests.
You may also be interested in...
In another sign of uncertainty for Alzheimer’s disease drug development, Lilly shakes things up with announcement of design changes for Phase III trial for solanezumab.
Phase III data presented in Athens shows clinical benefit for cognition and/or function in patients who are homozygous or heterozygous for the APOE4 gene.
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.